Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Emmanuelle Le Chatelier et al.|Science|2017Cited by 5.4k
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cellsYulong Gao, Mark J. Smyth, Arabella Young et al.|Nature Immunology|2017Cited by 639
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancerLisa Derosa, Benjamin Besse, Bertrand Routy et al.|Nature Medicine|2022Cited by 637
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trialBertrand Routy, Saman Maleki Vareki, John Lenehan et al.|Nature Medicine|2023Cited by 446
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Vincent Cattoir, Romain Daillère et al.|Science|2020Cited by 382